High Court grants declaratory relief in Fujifilm’s Humira patent dispute
The English High Court granted a novel form of declaratory relief in Fujifilm Kyowa Kirin Biologics v AbbVie Biotechnology [2017] EWHC 395 (Pat). The source describes the ruling as a way to help clear a product’s route to market where pending patent applications cannot be challenged in court.
The English High Court granted a novel type of declaratory relief in Fujifilm Kyowa Kirin Biologics v AbbVie Biotechnology [2017] EWHC 395 (Pat). Reporting on the judgment, Legal 500 describes it as the first ruling of its kind, with potential to ease the patent clearance burden for generic pharmaceutical companies preparing to launch products after basic patents expire. The article was published on 22 June 2017 but does not give the judgment’s exact date.
Fujifilm Kyowa Kirin Biologics wanted to bring a monoclonal antibody biosimilar to AbbVie’s Humira medication to market when AbbVie’s basic product patent expired in October 2018. However, AbbVie’s continually refreshed portfolio of patent applications concerning Humira dosage regimes potentially obstructed that route. According to the report, those applications were not allowed to reach grant. Fujifilm therefore could not ask the UK courts to revoke the patents or obtain declarations of non-infringement in respect of them.
The report places the dispute in the wider context of secondary patent applications covering dosage regimes and dosage forms. It explains that repeatedly filing applications and dropping them before grant can leave competitors facing uncertainty without an available validity challenge in court. The declaratory relief granted in this case offered a means of addressing that obstacle. The supplied extract does not reproduce the declaration’s precise terms, so it should not be read as establishing unrestricted clearance for every biosimilar launch.
For businesses assessing defence cover, this dispute highlights the importance of discussing patent clearance proceedings rather than assuming every procedural route is insured. GMG offers defence cover up to £5m, while pursuit cover up to £1m in year one is available only alongside defence; the treatment of declaratory proceedings should be checked.
DEFENCE UP TO £5M · PURSUIT UP TO £1M IN YEAR ONE · PURSUIT ONLY WITH DEFENCE
SOURCE: Legal 500
Summarised for general information only. Nothing here is legal advice or a statement of policy terms – cover is subject to underwriting and the policy wording.
